S181: MODAKAFUSP ALFA (TAK-573): UPDATED CLINICAL, PHARMACOKINETIC (PK), AND IMMUNOGENICITY RESULTS FROM A PHASE 1/2 STUDY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

• J. L. Kaufman,
• S. Atrash,
• , S. A. Holstein,
• O. Nadeem,
• D Benson,
• K. Suryanarayan,
• Y. Liu,
• C. Li,
• L. Yang,
• X. Parot,
• D. T. Vogl

Affiliations

J. L. Kaufman

1 Winship Cancer Institute of Emory University, Atlanta

S. Atrash

2 Haematology and blood disorders, Levine Cancer Institute, Charlotte

, S. A. Holstein

3 University of Nebraska Medical Center, Omaha

O. Nadeem

4 Dana-Farber Cancer Institute Boston, Boston

D Benson

5 Hematology, Ohio State University Comprehensive Cancer Center, Columbus

K. Suryanarayan

6 Oncology Clinical Research

Y. Liu

7 Statistical and Quantitative Sciences

C. Li

8 Takeda Development Center Americas, Inc. (TDCA), Lexington

L. Yang

8 Takeda Development Center Americas, Inc. (TDCA), Lexington

X. Parot

8 Takeda Development Center Americas, Inc. (TDCA), Lexington

D. T. Vogl

9 Hematologic Malignancies and Bone Marrow Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, United States of America